1 / 4

IVD Antibodies for Placental Growth Factor (PlGF) Marker

Creative Biolabs has developed many high quality in vitro diagnostics (IVD) antibodies against several disease markers, including placental growth factor (PlGF). With experienced scientists hammering at Creative Biolabs, we are confident in providing incomparable custom service to develop IVD antibodies of PlGF marker for the diagnosis of coronary artery disease (CAD).

Download Presentation

IVD Antibodies for Placental Growth Factor (PlGF) Marker

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. IVD Antibodies for Placental Growth Factor (PlGF) Marker Creative Biolabs has developed many high quality in vitro diagnostics (IVD) antibodies against several disease markers, including placental growth factor (PlGF). With experienced scientists hammering at Creative Biolabs, we are confident in providing incomparable custom service to develop IVD antibodies of PlGF marker for the diagnosis of coronary artery disease (CAD). PlGF is a member of the vascular endothelial growth factor (VEGF) family, which was initially found in the placenta, but was also discovered in a variety of other tissues. This protein is released as a glycosylated homodimer and the most widely known structural feature of PlGF is due to six cysteine residues of each monomer which form three intra-chain disulfide bonds, forming a special three-dimensional structure known as cystine-knot motif. PlGF serves a crucial role in a number of physiological and pathological situations, such as cardiovascular diseases (CVD), tumour progression and preeclampsia. It is a multitasking cytokine that enables to excite angiogenesis through direct or indirect mechanisms on account of its capacity to bind and activate VEGFR-1 receptor expressed in a number of cell types. PlGF seems to be stable in circulation and may be a powerful candidate as a biomarker for myocardial ischemia, plaque instability, and prognosis for patients with acute coronary syndrome (ACS).

  2. Figure 1. Schematic diagram of the indirect and direct angiogenic influences of PlGF and vascular endothelial growth factor B (VeGFB) on endothelial cells. PlGF indirectly excites angiogenesis through recruiting and activating a variety of cell types which upregulate VEGFA and other angiogenic factors, for example, stromal cell-derived factor 1 (SDF1), matrix metalloproteinase 9 (MMP9) and interleukin 8 (IL8). (Fischer, C. 2008) PlGF Marker of Coronary Artery Disease CAD, a most usual type of heart disease, is the primary cause of death in the United States. It occurs when the arteries that offer blood to heart muscle turn into hardened and narrowed. This is on account of the buildup of cholesterol and other material on the inner walls of arteries, and this buildup is known as atherosclerosis. Besides, CAD is able to weaken the heart muscle and resulting in heart failure and arrhythmias. Animal data reveals that PlGF is able to play as an early and major inflammatory instigator of atherosclerotic plaque instability. PlGF also acts an important role in predicting mortality and cardiovascular events in ESRD (end-stage renal disease) patients on dialysis. In addition, increased PlGF concentration is an independent biomarker of short term and long-term adverse outcome in patients with suspicious acute coronary

  3. syndrome (ACS). In the CAPTURE research, patients with ACS had increased PlGF levels contrasted to patients with noncardiac chest pain or stable angina. Figure 2. Graph shows the performance of PlGF, troponin T, high-sensitive troponin T, and soluble Fms-like tyrosine kinase 1 in the operating characteristic curves for the diagnosis of acute myocardial infarction. (Hochholzer, W. 2011) IVD Antibodies of PlGF Marker Biomarkers are usually regarded as proteins or enzymes which are detected in serum, plasma, or blood and can offer independent diagnostic and prognostic value through presenting an underlying disease state. As an inflammatory biomarker of CAD, PlGF has a promising role for the forecast of risk for developing CAD and is highly connected with severity of CAD. With the rapid development of in vitro diagnostics, IVD antibodies are more and more applied for immunology methods of IVD. Creative Biolabs offers a full range of IVD antibodies for the diagnosis of CAD and our high quality antibodies will absolutely contribute to the success of your project. Creative Biolabs offers high-affinity IVD antibody discovery and development services against PlGF marker to meet every customer's requirements. Creative Biolabs also provides other IVD antibodies. Please feel free to contact us for more information and a detailed quote. Reference

  4. 1. Fischer, C. (2008). “FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?.”Nature Reviews Cancer 8(12), 942-956. 2. Matsui, M. (2015). “Placental Growth Factor as a Predictor of Cardiovascular Events in Patients with CKD from the NARA-CKD Study.”Journal of the American Society of Nephrology ASN-2014080772. 3. Hochholzer, W. (2011). “Impact of soluble fms-like tyrosine kinase-1 and placental growth factor serum levels for risk stratification and early diagnosis in patients with suspected acute myocardial infarction.”European heart journal 32(3), 326-335. Related Services: IVD Antibody Development Services for sFlt-1 Marker IVD Antibodies for Myoglobin Marker IVD Antibodies for MR-proADM IVD Antibody Development Services for Copeptin Marker IVD Antibodies for PAPP-A Marker

More Related